Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab

Home/Pharma News | Posted 28/05/2024 post-comment0 Post your comment

In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.

Turkey 2016 COVER V16E31DG

The company’s biosimilar for autoimmune disease treatment Remsima (infliximab, which references Janssen’s Remicade) won a Peruvian Workers' Insurance System (EsSalud) tender. The company notes that the tender is the largest of its kind accounting for 81% of the total infliximab volume in Peru.

Celltrion intends to supply Remsima for one year beginning in May 2024 and anticipates that the product will have an 86% market share in Peru.

Additionally, Celltrion won a tender from the Peruvian Ministry of Health (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud, CENARES) for its trastuzumab biosimilar, Herzuma (which references Genentech’s Herceptin), used to treat breast and gastric cancer. The tender represents about half of the trastuzumab market in Peru. Celltrion will provide a one-year supply of Herzuma starting in July 2024.

Earlier in 2024, Celltrion won public tenders in Peru for its rituximab biosimilar, Truxima, as well as its adalimumab biosimilar, Yuflyma. 

The Korean company, through its local subsidiaries, has focused on building a network of contacts with healthcare providers, regulators, and government officials in Peru. Based on these activities, Celltrion has optimized and tailored its strategy for each tender, resulting in the winning of all four of its products.

Celltrion intends to keep up introducing more products and continue its expansion in Peru. They plan to launch in May 2024 Vegzelma, a bevacizumab biosimilar for treating colorectal and lung cancer.

The first biosimilar to receive approval in Peru was Celltrion’s monoclonal antibody Flixceli (infliximab) in 2016 [1]. That year, the Ministry of Health, MINSA, released a national biosimilar regulatory framework in 2016 in an effort to boost the domestic biologicals market [2].

Related articles
Regulatory landscape for biosimilars in Latin America 

Peru issues decree for the registration of medicines and biological products

Celltrion has renewed success with leukaemia biosimilar Truxima and expands markets in Europe and Latin America

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Peru [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-peru
2. GaBI Online - Generics and Biosimilars Initiative. The biosimilars market in Latin America: a summary [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/research/The-biosimilars-market-in-Latin-America-a-summary

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010